Top

Published in:

01-10-2008 | ssat plenary presentation

Use of Infliximab within 3 Months of Ileocolonic Resection is Associated with Adverse Postoperative Outcomes in Crohn’s Patients

Authors: Kweku A. Appau, Victor W. Fazio, Bo Shen, James M. Church, Bret Lashner, Feza Remzi, Aaron Brzezinski, Scott A. Strong, Jeffrey Hammel, Ravi P. Kiran

Published in: Journal of Gastrointestinal Surgery | Issue 10/2008

Abstract

Background

Few studies have evaluated preoperative infliximab use and postoperative outcomes in Crohn’s patients. Our aim was to evaluate 30-day postoperative outcomes for Crohn’s patients treated with infliximab within 3 months prior to ileocolonic resection.

Methods

The study is a retrospective evaluation of data for patients undergoing ileocolonic resection after 1998 from a prospective Crohn’s disease database. Patient characteristics and 30-day complications were compared for patients treated with infliximab within 3 months before surgery and an infliximab naïve group. The infliximab group was also compared with non-infliximab patients undergoing ileocolonic surgery before 1998.

Results

Sixty of 389 Crohn’s patients undergoing ileocolonic resection received infliximab. The infliximab and non-infliximab groups had similar characteristics, preoperative risk factors, and surgical procedure. However, steroid use was higher (p < 0.05) in the non-infliximab group while concurrent immunosuppressive use was higher (p < 0.001) in the infliximab group. Multivariate analysis showed infliximab use to be associated with 30-day postoperative readmission (p = 0.045), sepsis (p = 0.027), and intraabdominal abscess (p = 0.005). The presence of diverting stoma (n = 17) in the infliximab group was associated with lower risk of sepsis (0% vs. 27.9%, p = 0.013). Similar results were noted when the infliximab group was compared to the pre-infliximab patients.

Conclusions

Infliximab use within 3 months before surgery is associated with increased postoperative sepsis, abscess, and readmissions in Crohn’s patients. Diverting stoma may protect against these complications.

van Hogezand RA. Medical management of patients with difficult-to-treat inflammatory bowel disease. Neth J Med. 1994;45(2):55–59.PubMed

Rasenack J, Kreisel W. Conservative therapy of ulcerative colitis and Crohn disease. Fortschr Med. 1991;109(11):245–247.PubMed

Hanauer SB. Medical therapy for Crohn’s disease. Curr Opin Gastroenterol. 1999;15(4):308–314. doi:10.1097/00001574-199907000-00006 PubMedCrossRef

Hanauer SB. Clinical perspectives in Crohn’s disease. Turning traditional treatment strategies on their heads: current evidence for “step-up” versus “top-down”. Rev Gastroenterol Disord. 2007;7(Suppl 2):S17–22.PubMed

Oldenburg B, Hommes D. Biological therapies in inflammatory bowel disease: top-down or bottom-up? Curr Opin Gastroenterol. 2007;23(4):395–399. doi:10.1097/MOG.0b013e32815b601b PubMedCrossRef

Frikker MJ, Segall MM. The resectional reoperation rate for Crohn’s disease in a general community hospital. Dis Colon Rectum. 1983;26(5):305–309. doi:10.1007/BF02561704 PubMedCrossRef

Polle SW, Slors JF, Weverling GJ, Gouma DJ, Hommes DW, Bemelman WA. Recurrence after segmental resection for colonic Crohn’s disease. Br J Surg. 2005;92(9):1143–1149. doi:10.1002/bjs.5050 PubMedCrossRef

Sachar DB. Maintenance strategies in Crohn’s disease. Hospital Practice (1995) 1996;31(1):99–106.

Murray JJ, Schoetz DJ Jr, Nugent FW, Coller JA, Veidenheimer MC. Surgical management of Crohn’s disease involving the duodenum. Am J Surg. 1984;147(1):58–65. doi:10.1016/0002-9610(84)90035-7 PubMedCrossRef

10.

Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T. et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997;337(15):1029–1035. doi:10.1056/NEJM199710093371502 PubMedCrossRef

11.

Kornbluth A. Infliximab approved for use in Crohn’s disease: a report on the FDA GI Advisory Committee conference. Inflamm Bowel Dis. 1998;4(4):328–329. doi:10.1002/ibd.3780040415 PubMedCrossRef

12.

Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF. et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–1549. doi:10.1016/S0140-6736(02)08512-4 PubMedCrossRef

13.

Feagan BG, Yan S, Bala M, Bao W, Lichtenstein GR. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol. 2003;98(10):2232–2238. doi:10.1111/j.1572-0241.2003.07674.x PubMedCrossRef

14.

Andus T, Stange EF, Hoffler D, Keller-Stanislawski B. Suspected cases of severe side effects after infliximab (Remicade) in Germany. Med Klin (Munich). 2003;98(8):429–436. doi:10.1007/s00063-003-1282-9 CrossRef

15.

Hansen RA, Gartlehner G, Powell GE, Sandler RS. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol. 2007;5(6):729–735. doi:10.1016/j.cgh.2007.02.016 PubMedCrossRef

16.

Byrne CM, Solomon MJ, Young JM, Selby W, Harrison JD. Patient preferences between surgical and medical treatment in Crohn’s disease. Dis Colon Rectum. 2007;50(5):586–597. doi:10.1007/s10350-006-0847-0 PubMedCrossRef

17.

Chang J, Girgis L. Clinical use of anti-TNF-alpha biological agents-a guide for GPs. Aust Fam Physician. 2007;36(12):1035–1038.PubMed

18.

Selvasekar CR, Cima RR, Larson DW, Dozois EJ, Harrington JR, Harmsen WS. et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007;204(5):956–962. discussion 962–953. doi:10.1016/j.jamcollsurg.2006.12.044 PubMedCrossRef

19.

Mor IJ, Vogel JD, da Luz Moreira A, Shen B, Hammel J, Remzi FH. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 2008;51(8):1202–1207.PubMedCrossRef

20.

Colombel JF, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T. et al. Early postoperative complications are not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004;99(5):878–883. doi:10.1111/j.1572-0241.2004.04148.x PubMedCrossRef

21.

Marchal L, D’Haens G, Van Assche G, Vermeire S, Noman M, Ferrante M. et al. The risk of post-operative complications associated with infliximab therapy for Crohn’s disease: a controlled cohort study. Aliment Pharmacol Ther. 2004;19(7):749–754. doi:10.1111/j.1365-2036.2004.01904.x PubMedCrossRef

22.

Cornillie F, Shealy D, D’Haens G, Geboes K, Van Assche G, Ceuppens J. et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease. Aliment Pharmacol Ther. 2001;15(4):463–473. doi:10.1046/j.1365-2036.2001.00956.x PubMedCrossRef

23.

Bratcher JM, Korelitz BI. Toxicity of infliximab in the course of treatment of Crohn’s disease. Expert Opin Drug Saf. 2006;5(1):9–16. doi:10.1517/14740338.5.1.9 PubMedCrossRef

24.

Reddy JG, Loftus EV Jr. Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am. 2006;35(4):837–855. doi:10.1016/j.gtc.2006.09.008 PubMedCrossRef

25.

Weston-Petrides GK, Lovegrove RE, Tilney HS, Heriot AG, Nicholls RJ, Mortensen NJ. et al. Comparison of outcomes after restorative proctocolectomy with or without defunctioning ileostomy. Arch Surg. 2008;143(4):406–412. doi:10.1001/archsurg.143.4.406 PubMedCrossRef

26.

Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum. 2005;34(6):819–836. doi:10.1016/j.semarthrit.2004.11.006 PubMedCrossRef

27.

Kalkay MN, Cordoba I, Plevy D. The nonreflux determinant of esophagitis. Am J Gastroenterol. 1975;63(2):135–146.PubMed

28.

Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deem RL, Shealy D. et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn’s disease. J Immunol. 1997;159(12):6276–6282.PubMed

Title: Use of Infliximab within 3 Months of Ileocolonic Resection is Associated with Adverse Postoperative Outcomes in Crohn’s Patients
Authors: Kweku A. Appau
Victor W. Fazio
Bo Shen
James M. Church
Bret Lashner
Feza Remzi
Aaron Brzezinski
Scott A. Strong
Jeffrey Hammel
Ravi P. Kiran
Publication date: 01-10-2008
Publisher: Springer-Verlag
Published in: Journal of Gastrointestinal Surgery / Issue 10/2008
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-008-0646-0

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Use of Infliximab within 3 Months of Ileocolonic Resection is Associated with Adverse Postoperative Outcomes in Crohn’s Patients

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2008

Laparoscopy-Assisted Distal Gastrectomy for Gastric Cancer

Eradication of Barrett Esophagus with Early Neoplasia by Radiofrequency Ablation, with or without Endoscopic Resection

Re: An Antecolic Roux-En-Y Type Reconstruction Decreased Delayed Gastric Emptying After Pylorus-Preserving Pancreatoduodenectomy by Murakami et al.

Loss of Heterozygosity Predicts Poor Survival After Resection of Pancreatic Adenocarcinoma

Surgical Management of Early-Stage Hepatocellular Carcinoma: Resection or Transplantation?

Epigenetic Regulation of WNT Signaling Pathway Genes in Inflammatory Bowel Disease (IBD) Associated Neoplasia